Table 1.
Low-dose chemo-irradiation enhances the anti-tumor effect of alloreactive NK cells that had developed and matured in the tumor-bearing fully MHC-mismatched host
| Exp. no. |
Treatment group (all had s.c. 4T1 breast cancer) | Palpable tumor incidence | |||
|---|---|---|---|---|---|
| At day 8 | p value | At the end of the experiment | p value | ||
| 1. | No further treatment | 0/12 | 10/12 | ||
| 2. | No further treatment | 0/12 | – | 10/12 | <0.01 |
| Chemo-irradiation | 0/12 | Reference | 2/12 | Reference | |
| 3. | No further treatment | 6/16 | – | 11/16 | 0.01 |
| Chemo-irradiation | 5/16 | Reference | 3/16 | Reference | |
| Anti-AsialoGM1 NK cell depletion at days 0, 5, and 10 and chemo-irradiation | 10/16 | 0.12 | 8/16 | 0.14 | |
| 4. | No further treatment | 4/16 | – | 9/16 | 0.07 |
| Chemo-irradiation | 4/16 | Reference | 3/16 | Reference | |
| Anti-NK1.1 NK cell depletion from day 0 and chemo-irradiation | 12/16 | 0.01 | 13/16 | <0.01 | |
Palpable s.c. 4T1 breast cancer incidence as measured at day 8 (i.e., the day of onset of chemo-irradiation in the appropriate groups) and at the end of the experiment (130 days in experiments 1–3, 100 days in experiment 4)